Blog
RSS FeedPosted by Michael Wonder on 16 Mar 2020
Regulatory and health technology assessment advice on post‐licensing and post‐launch evidence generation is a foundation for lifecycle data collection for medicines
11 March 2020 - The understanding of the benefit risk profile, and relative effectiveness of a new medicinal product, are initially ...
Posted by Michael Wonder on 09 Mar 2020
HHS finalises historic rules to provide patients more control of their health data
9 March 2020 - Final rules require access to health information, spur innovation and aim to end information blocking ...
Posted by Michael Wonder on 22 Feb 2020
FDA launches new resource to provide easily accessible, more accurate historical drug approval data
21 February 2020 - FDA is launching a new resource to assist external and agency researchers collecting historical information about ...
Posted by Michael Wonder on 05 Feb 2020
NICE plans to widen the net for data it uses in guidance
5 February 2020 - UK cost-effectiveness body NICE has said it intends to use a broader range of data and ...
Posted by Michael Wonder on 04 Feb 2020
Broader types of data to be used in development of NICE guidance
4 February 2020 - An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact ...
Posted by Michael Wonder on 29 Jan 2020
FDA launches mobile-friendly database with information on life-saving HIV drugs as part of ongoing mission to empower the public through increased access to information and data
29 January 2020 - Interactive tool offers information on ARVs eligible for purchase under the President’s Emergency Plan for AIDS Relief ...
Posted by Michael Wonder on 25 Jan 2020
Registry-data – of sufficient quality – are suitable for the extended benefit assessment of drugs
24 January 2020 - Rapid report shows how routine practice data should be collected and processed. ...
Posted by Michael Wonder on 21 Jan 2020
Will the FDA give the go-ahead to a prescription video game? The wait goes on, as new data come in.
21 January 2020 - In mid 2018, the startup Akili Interactive Labs asked the Food and Drug Administration to let ...
Posted by Michael Wonder on 20 Jan 2020
Ten recommendations to unlock the potential of big data for public health in the EU
20 January 2020 - The joint Big Data Task Force of EMA and the Heads of Medicines Agencies proposes ten ...
Posted by Michael Wonder on 20 Jan 2020
Sharing health care data with digital giants
16 January 2020 - Overcoming obstacles and reaping benefits while protecting patients. ...
Posted by Michael Wonder on 14 Jan 2020
FDA approves drugs faster than ever but relies on weaker evidence, researchers find
14 January 2020 - The FDA has gotten faster at approving new prescription drugs over the past four decades, but ...
Posted by Michael Wonder on 09 Jan 2020
FDA real world evidence to be made available on Google Cloud
8 January 2020 - The company is making the agency's open-source MyStudies platform available, enabling for easier access to data for ...
Posted by Michael Wonder on 03 Jan 2020
Additional evidence needed to assess histology-independent cancer drugs says paper co-authored by NICE staff
2 January 2020 - Paper looks at how histology-independent cancer drugs might be appraised. ...
Posted by Michael Wonder on 17 Dec 2019
Report on the collection of under co-payment data 2018-19
17 December 2019 - The report on the collection of under co-payment data 2018-19 is now available. ...
Posted by Michael Wonder on 07 Dec 2019
Insurer NIB wants access to members’ genetic information
6 December 2019 - Health insurer NIB wants to use genetic information and My Health Record data to calculate the ...